primaquine and Eye Infections, Parasitic

primaquine has been researched along with Eye Infections, Parasitic in 1 studies

Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.

Eye Infections, Parasitic: Mild to severe infections of the eye and its adjacent structures (adnexa) by adult or larval protozoan or metazoan parasites.

Research

Studies (1)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Fever Clearance Time (FCT)

Measure of body temperature every 12 hours through day 7 was used to determine the time (to nearest 12 hours) from initiation of treatment until subjects temperature decreased to 37.2C and remained at or below that level for a minimum of 24 hours. (NCT01290601)
Timeframe: through day 7

Adequate Clinical Response (ACR) of Tafenoquine: 28 Day Cure Rate

A subject will be considered a success (cure) if they have an Adequate Clinical Response (ACR). Tafenoquine was efficacious if the lower bound of the two-sided 90% confidence interval for the day 28 cure rate was not less than 85% (NCT01290601)
Timeframe: 28 Days

Number of Subjects Without Relapse of P. Vivax

"Number of subjects without relapse of P. vivax at 2, 3 and 4 months~- Blood smears were obtained at Days 28, 60, 90 and 120 to confirm the continued absence of P. vivax parasitemia" (NCT01290601)
Timeframe: Day 28, Months 2, 3 and 4

Parasite and Gametocyte Clearance Time (PCT and GCT)

Serial blood smears to detect the presence of P. vivax parasites and gametocytes, conducted every 12 hours up to and including day 7, until blood smear became negative were utilized to determine the time to clearance. PCT and GCT were considered cleared if 2 consecutive blood smears were negative. (NCT01290601)
Timeframe: up to day 7 after baseline smear

Safety and Tolerability of Tafenoquine as Defined by Most Common Adverse Events (AEs)

To evaluate the safety and tolerability of the tafenoquine dosing regimens as defined by the most common AE's overall, occurring in >10% of subjects in either treatment group (NCT01290601)
Timeframe: 90 Days

Trials

1 trial available for primaquine and Eye Infections, Parasitic